Amy Butts, PA
Physician Assistant · Wellsburg, WVNPI 1184629404
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $181,806 of the $258,461 with a category attached, or 70.3%. 22 manufacturers reported payments, led by Novo Nordisk at 51.5% of the total. 2025 is the largest year on record at $77,341, 2.4 times the $32,677 reported in 2021. Among physician assistant clinicians in WV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 519 payments — averaging $498.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$133K
- Abbott$51K
- Bayer$33K
- Corcept Therapeutics$22K
- Xeris Pharmaceuticals, Inc.$14K
- Ascensia Diabetes Care US Inc.$3K
- plus $3K from 16 others
What the payments were for
- Consulting fees$14,5156%
- Speaking & faculty fees$181,80670%
- Travel & lodging$48,46919%
- Food & beverage$13,5365%
- Education$750%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 223 | $133,114 |
| Abbott | 108 | $51,261 |
| Bayer | 42 | $32,601 |
| Corcept Therapeutics | 51 | $22,476 |
| Xeris Pharmaceuticals, Inc. | 41 | $13,547 |
| Ascensia Diabetes Care US Inc. | 5 | $2,784 |
| Sanofi-aventis U.S. LLC | 4 | $899 |
| Mannkind Corporation | 8 | $497 |
| Tandem Diabetes Care, Inc. | 10 | $462 |
| Amgen | 7 | $165 |
| Dexcom, Inc. | 1 | $97 |
| Insulet Corporation | 2 | $96 |
| Cequr Corporation | 1 | $79 |
| Lilly USA, LLC | 4 | $77 |
| Madrigal Pharmaceuticals | 2 | $56 |
| Medtronic | 1 | $50 |
| Ascendis Pharma Endocrinology Inc | 2 | $49 |
| Pfizer | 2 | $46 |
| Neurocrine Biosciences, Inc. | 1 | $33 |
| Sequel Med Tech, LLC | 2 | $30 |
| Amneal Pharmaceuticals LLC | 1 | $22 |
| BETA Bionics, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$69,012
- Ozempic$53,436
- FREESTYLE LIBRE 3$42,012
- Kerendia$32,120
- Korlym$21,623
- GVOKE HYPOPEN$12,130
- EVERSENSE E3 SENSOR KIT - RETAIL$2,784
- GVOKE PFS$900
- TOUJEO$655
- t:slim X2 Insulin Pump with Control-IQ$224
- TZIELD$121
- AFREZZA$117
How this compares
$258,461 in reported general payments places this provider in the 95th percentile of 833 physician assistant providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 24 | $825,140 |
| OzempicSemaglutide | 505 | $619,609 |
| JardianceEmpagliflozin | 284 | $261,722 |
| TrulicityDulaglutide | 194 | $241,542 |
| Tresiba Flextouch U-100Insulin Degludec | 191 | $128,220 |
| MounjaroTirzepatide | 98 | $112,334 |
| FarxigaDapagliflozin Propanediol | 87 | $88,193 |
| RybelsusSemaglutide | 54 | $72,298 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 56 | $65,732 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 88 | $63,236 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 118 | $58,635 |
| Tresiba Flextouch U-200Insulin Degludec | 66 | $58,274 |
| JanumetSitagliptin Phos/Metformin Hcl | 51 | $56,009 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 56 | $56,004 |
| JanuviaSitagliptin Phosphate | 61 | $55,420 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $22,476 | $825,14024 claims |
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6, Novolog | $133,114 | $774,358668 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Lyumjev, Humalog | $77 | $388,752359 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $899 | $56,00456 claims |
| BayerKerendia | $32,601 | $42,31451 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 833 physician assistant providers in West Virginia.
Other physician assistant in Wellsburg
- Alexander EpperlySouth Charleston$21K
- Kelley WhoolerySouth Charleston$17K
- Jordan BrewerMorgantown$15K
- Tasha ElswickWinfield$14K
- Frances PauleyCharleston$14K
- Danielle MolinaCharleston$12K
- Erik AndersonSouth Charleston$11K
- Catherine EnsingerParkersburg$11K
- Gregory PorterSouth Charleston$11K
- Jason TrustyCharleston$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.